Literature DB >> 26573389

Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

A Klingenstein1, C Fürweger2, A K Mühlhofer3, S F Leicht3, U C Schaller3, A Muacevic2, B Wowra2, C Hintschich3, K H Eibl3.   

Abstract

PURPOSE: To compare quality of life (QoL) in patients with uveal melanoma after enucleation and stereotactic radiosurgery to that in an age-matched patient collective.
METHODS: QoL was assessed in a cross-sectional survey and compared among 32 uveal melanoma patients after enucleation, 48 patients after stereotactic radiosurgery (CyberKnife(®); Accuray(®) Incorporated, Sunnyvale, CA, USA), and an age-matched control group of 35 patients, using the SF-12 Health Survey. Statistical analysis was performed with Fisher's exact test, Student's t test, one-way ANOVA analysis, Wilcoxon rank-sum (Mann-Whitney test), and ordered logistic regression for multivariate analysis.
RESULTS: There was no significant difference in QoL between patients treated by stereotactic radiosurgery and the age-matched control group. After enucleation, patients presented significantly lower values in Physical Functioning (PF), Role Physical (RP), and Role Emotional (RE) compared to the radiosurgery and control group. To control for the overall QoL lowering effect of visual loss, the QoL of the patients who underwent enucleation was compared with the QoL of patients suffering severe functional loss after CyberKnife radiosurgery in a subgroup analysis, which showed no statistically significant difference. The number of comorbidities had a significant impact on QoL in multivariate analysis.
CONCLUSIONS: Superior performance in PF, RP, and RE suggests that CyberKnife represents a suitable first-line therapy for uveal melanoma. In cases with painful amaurosis or vast tumor recurrence, enucleation can be performed with an acceptable QoL outcome.

Entities:  

Keywords:  CyberKnife; Enucleation; Quality of life; SF-12 Health Survey; Stereotactic radiosurgery; Uveal melanoma

Mesh:

Year:  2015        PMID: 26573389     DOI: 10.1007/s00417-015-3216-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Quality of life in patients with choroidal melanoma: a pilot study.

Authors:  B M Melia; C S Moy; L McCaffrey
Journal:  Ophthalmic Epidemiol       Date:  1999-03       Impact factor: 1.648

3.  Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3).

Authors:  M J Hjermstad; P M Fayers; K Bjordal; S Kaasa
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

4.  Population-based incidence of uveal melanoma in various races and ethnic groups.

Authors:  Dan-Ning Hu; Guo-Pei Yu; Steven A McCormick; Susan Schneider; Paul T Finger
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

Review 5.  Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond.

Authors:  T Kivelä; E Kujala
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

6.  Development of a streamlined, non-invasive robotic radiosurgery method for treatment of uveal melanoma.

Authors:  Alexander Muacevic; Martin Nentwich; Berndt Wowra; Sibylle Staerk; Anselm Kampik; Ulrich Schaller
Journal:  Technol Cancer Res Treat       Date:  2008-10

Review 7.  Depression in cancer: new developments regarding diagnosis and treatment.

Authors:  Charles L Raison; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

8.  Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3.

Authors:  Michele Melia; Claudia S Moy; Sandra M Reynolds; James A Hayman; Timothy G Murray; Kenneth R Hovland; John D Earle; Natalie Kurinij; Li Ming Dong; Päivi H Miskala; Connie Fountain; David Cella; Carol M Mangione
Journal:  Arch Ophthalmol       Date:  2006-02

9.  American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients.

Authors:  Carol L Shields; Swathi Kaliki; Minoru Furuta; Enzo Fulco; Carolina Alarcon; Jerry A Shields
Journal:  Ophthalmology       Date:  2013-05-09       Impact factor: 12.079

10.  Influence of uveal melanoma therapy on patients' quality of life: a psychological study.

Authors:  Sophie Chabert; Michaela Velikay-Parel; Martin Zehetmayer
Journal:  Acta Ophthalmol Scand       Date:  2004-02
View more
  4 in total

Review 1.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

2.  Screening for Predictive Parameters Requiring Psycho-Oncological Intervention via the National Comprehensive Cancer Network Distress Thermometer in the Follow-Up of Uveal Melanoma Patients.

Authors:  Annemarie Klingenstein; Christina Samel; Aylin Garip-Kuebler; Siegfried G Priglinger; Paul I Foerster
Journal:  Clin Ophthalmol       Date:  2020-11-09

3.  Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis.

Authors:  Christopher A Barker; Anna Kozlova; Alexander N Shoushtari; Jennifer L Hay; Jasmine H Francis; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2019-09-27

4.  Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma.

Authors:  Johannes Gollrad; Christopher Rabsahl; Aline-Isabel Riechardt; Jens Heufelder; Andrea Stroux; Ute Goerling; Antonia Joussen; Volker Budach; Dirk Boehmer
Journal:  Radiat Oncol       Date:  2021-09-08       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.